RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Budget impact model of omalizumab in the treatment of chronic spontaneous urticaria In Italy
Ravasio, R., Cawson, M., McBride, D., Balp, M., & Roccia, A. (2015). Budget impact model of omalizumab in the treatment of chronic spontaneous urticaria In Italy. Value in Health, 18(7), A417. Article PSS13. https://doi.org/10.1016/j.jval.2015.09.537
Objectives A 3-year budget-impact model (BIM) was developed to estimate the impact on the Italian health care budget of introducing omalizumab for the treatment of patients with chronic spontaneous urticaria (CSU) with inadequate response to H1-antihistamines (licensed dose).
Methods The model considered patients with CSU aged ≥12 years. The BIM was developed from the perspective of the Italian National Health Service (NHS). Only direct medical costs were considered: drug costs (omalizumab 300mg and H1-antihistamines), drug-related costs (administration, screening and monitoring) and disease-related costs (physician, emergency department and hospitalisation). Omalizumab 300mg uptake was assumed to be 10.9% in the first year, 17.5% in the second year and 28.6% in the third year (only treatments that would be substituted for omalizumab were included in the market treatment shares). Ex-factory prices (included all discounts) and National Tariffs were considered to estimate costs of drug and medical resource used, respectively. Costs were assessed in Euros (2015 values).
Results The total number of patients treated in the first year was estimated to be 27,490, with 2,996 of those treated with omalizumab, increasing to a total of approximately 27,708 in the third year, with 7,925 receiving omalizumab. Considering only drug costs, the incremental budget impact of introducing omalizumab 300mg to the current market share was estimated to be €4.4 million in the first year, increasing to €11.7 million in the third year. Considering total direct medical costs, it was possible to show that part of the incremental drug costs of introducing omalizumab 300mg was offset by decrease in other resources: €1.4 million (total incremental budget) in the first year to €3.7 million in the third year.
Conclusions The use of omalizumab to treat CSU with inadequate response to H1-antihistamines increases drug and drug-related costs, but this is partially offset by reduced disease-related costs in omalizumab recipients.